Gustavo E Velásquez

16PUBLICATIONS
45CO-AUTHORS
Predictive and prognostic markersPharmacogenomicsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples and disability
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Apr 16, 2026
Tuberculosis Disease Severity Assessment Using Clinical Variables and Radiology Enabled by Artificial Intelligence.

|Mar 06, 2026
Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis.

Eunsol Yang, Pieter Van Brantegem, Charles A Peloquin

|Nov 18, 2025
Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures.

Matthew T Murrill, Gustavo E Velásquez, John D Szumowski

|Aug 08, 2025
Tuberculosis infection screening recommendations for targeted immunotherapies: comparison of U.S. prescribing information, clinical resources and quality measures.

Matthew T Murrill, Gustavo E Velásquez, John D Szumowski

|Apr 16, 2025
Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial.

Elizabeth Mackay, Gareth Platt, Charles A Peloquin

|Jan 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.

Lorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez

Pageof 3

Frequent Collaborators

3 joint publications

Payam Nahid

2 joint publications

Charles A Peloquin

2 joint publications

Leonid Lecca

2 joint publications

Geraint R Davies